Emerging Treatment Approaches for Parkinson’s Disease
Parkinson’s disease (PD) is the second most common neurodegenerative disease, manifesting as a characteristic movement disorder with a number of additional non-motor features. The pathological hallmark of PD is the presence of intra-neuronal aggregates of α-synuclein (Lewy bodies). The movement diso...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-10-01
|
| Series: | Frontiers in Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fnins.2018.00693/full |
| _version_ | 1818415931631599616 |
|---|---|
| author | Thomas B. Stoker Thomas B. Stoker Thomas B. Stoker Kelli M. Torsney Kelli M. Torsney Roger A. Barker Roger A. Barker Roger A. Barker |
| author_facet | Thomas B. Stoker Thomas B. Stoker Thomas B. Stoker Kelli M. Torsney Kelli M. Torsney Roger A. Barker Roger A. Barker Roger A. Barker |
| author_sort | Thomas B. Stoker |
| collection | DOAJ |
| description | Parkinson’s disease (PD) is the second most common neurodegenerative disease, manifesting as a characteristic movement disorder with a number of additional non-motor features. The pathological hallmark of PD is the presence of intra-neuronal aggregates of α-synuclein (Lewy bodies). The movement disorder of PD occurs largely due to loss of dopaminergic neurons of the substantia nigra, resulting in striatal dopamine depletion. There are currently no proven disease modifying treatments for PD, with management options consisting mainly of dopaminergic drugs, and in a limited number of patients, deep brain stimulation. Long-term use of established dopaminergic therapies for PD results in significant adverse effects, and there is therefore a requirement to develop better means of restoring striatal dopamine, as well as treatments that are able to slow progression of the disease. A number of exciting treatments have yielded promising results in pre-clinical and early clinical trials, and it now seems likely that the landscape for the management of PD will change dramatically in the short to medium term future. Here, we discuss the promising regenerative cell-based and gene therapies, designed to treat the dopaminergic aspects of PD whilst limiting adverse effects, as well as novel approaches to reducing α-synuclein pathology. |
| first_indexed | 2024-12-14T11:42:50Z |
| format | Article |
| id | doaj.art-5f1cb9ec33054e8cb4523bb5d4c69a73 |
| institution | Directory Open Access Journal |
| issn | 1662-453X |
| language | English |
| last_indexed | 2024-12-14T11:42:50Z |
| publishDate | 2018-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neuroscience |
| spelling | doaj.art-5f1cb9ec33054e8cb4523bb5d4c69a732022-12-21T23:02:44ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2018-10-011210.3389/fnins.2018.00693419092Emerging Treatment Approaches for Parkinson’s DiseaseThomas B. Stoker0Thomas B. Stoker1Thomas B. Stoker2Kelli M. Torsney3Kelli M. Torsney4Roger A. Barker5Roger A. Barker6Roger A. Barker7John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United KingdomWellcome Trust – Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge, United KingdomDepartment of Neurology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United KingdomJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United KingdomDepartment of Medicine for the Elderly, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United KingdomJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United KingdomWellcome Trust – Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge, United KingdomDepartment of Neurology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United KingdomParkinson’s disease (PD) is the second most common neurodegenerative disease, manifesting as a characteristic movement disorder with a number of additional non-motor features. The pathological hallmark of PD is the presence of intra-neuronal aggregates of α-synuclein (Lewy bodies). The movement disorder of PD occurs largely due to loss of dopaminergic neurons of the substantia nigra, resulting in striatal dopamine depletion. There are currently no proven disease modifying treatments for PD, with management options consisting mainly of dopaminergic drugs, and in a limited number of patients, deep brain stimulation. Long-term use of established dopaminergic therapies for PD results in significant adverse effects, and there is therefore a requirement to develop better means of restoring striatal dopamine, as well as treatments that are able to slow progression of the disease. A number of exciting treatments have yielded promising results in pre-clinical and early clinical trials, and it now seems likely that the landscape for the management of PD will change dramatically in the short to medium term future. Here, we discuss the promising regenerative cell-based and gene therapies, designed to treat the dopaminergic aspects of PD whilst limiting adverse effects, as well as novel approaches to reducing α-synuclein pathology.https://www.frontiersin.org/article/10.3389/fnins.2018.00693/fullα-synucleinnovel therapiesParkinson’s diseaseregenerative therapiesstem cells |
| spellingShingle | Thomas B. Stoker Thomas B. Stoker Thomas B. Stoker Kelli M. Torsney Kelli M. Torsney Roger A. Barker Roger A. Barker Roger A. Barker Emerging Treatment Approaches for Parkinson’s Disease Frontiers in Neuroscience α-synuclein novel therapies Parkinson’s disease regenerative therapies stem cells |
| title | Emerging Treatment Approaches for Parkinson’s Disease |
| title_full | Emerging Treatment Approaches for Parkinson’s Disease |
| title_fullStr | Emerging Treatment Approaches for Parkinson’s Disease |
| title_full_unstemmed | Emerging Treatment Approaches for Parkinson’s Disease |
| title_short | Emerging Treatment Approaches for Parkinson’s Disease |
| title_sort | emerging treatment approaches for parkinson s disease |
| topic | α-synuclein novel therapies Parkinson’s disease regenerative therapies stem cells |
| url | https://www.frontiersin.org/article/10.3389/fnins.2018.00693/full |
| work_keys_str_mv | AT thomasbstoker emergingtreatmentapproachesforparkinsonsdisease AT thomasbstoker emergingtreatmentapproachesforparkinsonsdisease AT thomasbstoker emergingtreatmentapproachesforparkinsonsdisease AT kellimtorsney emergingtreatmentapproachesforparkinsonsdisease AT kellimtorsney emergingtreatmentapproachesforparkinsonsdisease AT rogerabarker emergingtreatmentapproachesforparkinsonsdisease AT rogerabarker emergingtreatmentapproachesforparkinsonsdisease AT rogerabarker emergingtreatmentapproachesforparkinsonsdisease |